Genvec Inc (GNVC) 0.53 $GNVC
GenVec Reports Second Quarter 2016 Financial Results
PR Newswire - Fri Aug 05, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the second quarter ended June 30, 2016. For the three months ended June 30, 2016, the company reported a net loss of $1.2 million or $0.06 per share on revenues of $26,000. This compares to a net loss of $1.9 million or $0.11 per share on revenues of $127,000 for the same period in the prior year. For the six months ended June 30, 2016, the company reported a net loss of $3.1 million or $0.16 per share on revenues of $0.3 million. This compares to a net loss of $3.4 million or $0.21 per share on revenues of $0.5 million for the same period in the prior year. The company ended the second quarter of 2016 with $9.6 million in cash and cash equivalents.
GNVC: 0.53 (-0.04)
Can DENTSPLY (XRAY) Spring an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:15AM CDT
DENTSPLY SIRONA Inc. (XRAY) is expected to report second-quarter 2016 results on Aug 5.
GNVC: 0.53 (-0.04), ANIP: 59.74 (-1.12), XRAY: 61.46 (-0.04), COO: 185.92 (-0.46)
GenVec Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the first quarter ended March 31, 2016. For the three months ended March 31, 2016, the company reported a net loss of $1.9 million, or $0.11 per share, compared with a net loss of $1.5 million, or $0.09 per share, for the three months ended March 31, 2015. The company ended the first quarter with $6.9 million in cash, cash equivalents, and liquid investments.
GNVC: 0.53 (-0.04)
GenVec Provides Update on Hearing Loss Clinical Program
PR Newswire - Mon May 02, 6:00AM CDT
GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced today that it was notified by its collaborator Novartis that the Data Safety Monitoring Board (DSMB) for the Phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss has recommended that the trial continue, subject to approval by the U.S. Food and Drug Administration (FDA). This recommendation was based on a review of safety and efficacy data from the nine patients currently enrolled in the study. Novartis is developing CGF166, GenVec's lead product candidate for hearing loss, under a Research Collaboration and License Agreement with GenVec. As previously disclosed, on January 8, 2016, GenVec was notified by Novartis that enrollment was paused in the clinical study for CGF166 in accordance with criteria in the trial protocol.
GNVC: 0.53 (-0.04), NVS: 78.77 (-0.57)
GenVec Provides Investor Update
PR Newswire - Wed Jan 20, 6:00AM CST
GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, provided an update to investors on recent developments and the company's strategic focus.
GNVC: 0.53 (-0.04), NVS: 78.77 (-0.57)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of GenVec, Inc. (GNVC)
PR Newswire - Mon Jan 11, 11:56AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of GenVec, Inc. ("GenVec" or the "Company"
(Nasdaq: GNVC). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
GNVC: 0.53 (-0.04)
GenVec Receives Notice of Allowance for Patent Application Providing Broad Protection of Its Gorilla Adenovectors
PR Newswire - Wed Dec 02, 7:00AM CST
GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced today that it received a notice of allowance for its patent application entitled "Affenadenovirus (Gorilla) or Adenoviral Vectors and Methods of Use" from the U.S. Patent and Trademark Office. The allowed claims cover composition of matter for the company's proprietary adenovectors isolated from mountain gorillas, including potential adjustments and additions that may be introduced to engineer these vectors for optimal suitability and performance in a variety of therapeutic and vaccine applications. One key advantage of our approach is that most people do not have pre-existing immunity to gorilla vectors. Such pre-existing immunity can interfere with vectors derived from more commonly encountered viruses and viral serotypes.
GNVC: 0.53 (-0.04)
GenVec Reports Third Quarter 2015 Financial Results
PR Newswire - Mon Nov 09, 7:00AM CST
GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, reported financial results for the third quarter ended September 30, 2015. For the three months ended September 30, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.2 million, compared with a net loss of $1.6 million, or $0.10 per share, on revenues of $0.3 million, for the same period in the prior year. For the nine months ended September 30, 2015, GenVec reported a net loss of $4.9 million, or $0.30 per share, on revenues of $0.7 million, compared with a net loss of $4.2 million, or $0.27 per share, on revenues of $2.5 million, for the same period in the prior year. GenVec ended the third quarter of 2015 with $9.9 million in cash, cash equivalents and investments.
GNVC: 0.53 (-0.04)
GenVec Expands I.P. Portfolio With Issuance Of U.S. And European Patents For Monkey Adenoviral Vectors
PR Newswire - Mon Sep 28, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that on September 15, 2015, the U.S. Patent and Trademark Office issued patent 9133248, covering methods of propagating proprietary gene delivery adenovectors isolated from new and old world monkeys. This patent complements European Patent No. 2498791, "Methods of Propagating Monkey Adenoviral Vectors". Patent applications in this family are also pending in Japan, China, India and Canada as well as other inventive claims in divisional applications. GenVec's monkey adenovectors provide additional, complementary features to our already broad platform providing greater flexibility to efficiently address a wide variety of gene delivery applications. In addition, GenVec's entire portfolio of vectors grow to high yields in our proprietary cell lines and can be readily manufactured under GMP conditions making them strong candidates for therapeutic use.
GNVC: 0.53 (-0.04)
GenVec (GNVC) Shows Strength: Stock Moves Up 18.7%
Zacks Equity Research - Zacks Investment Research - Mon Sep 21, 7:51AM CDT
GenVec, Inc. (GNVC) was a big mover last session, as its shares rose almost 19% on the day.
GNVC: 0.53 (-0.04), GILD: 78.38 (+0.46)
GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines
PR Newswire - Wed Jun 03, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced a multi-faceted collaboration with Dr. David T. Curiel and his team from the School of Medicine at Washington University at St. Louis (WUSTL). Dr. Curiel is the director of the Biologic Therapeutic Center and the Cancer Biology Division within the Department of Radiation Oncology.
GNVC: 0.53 (-0.04)
GenVec Highlights Proprietary Gorilla Vectors At ASGCT Presentation
PR Newswire - Thu May 14, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) announced today that Douglas E. Brough, the company's chief scientific officer, gave a presentation entitled "Gorilla Adenovirus Vectors for Molecular Therapeutics and Vaccines" at the 18th Annual Meeting of the American Society of Gene & Cell Therapy. The presentation highlighted the results of preclinical research conducted using the company's propriety adenovirus vectors originally isolated from mountain gorillas. These adenovectors have demonstrated superior performance to induce high level durable antigen specific antibody and T cell responses in GenVec's preclinical models for respiratory syncytial virus, herpes simplex virus, and malaria from a single administration. GenVec is working to test these 'gorilla Ads' in a variety of configurations through research conducted by its own laboratories and through collaborations and partnerships.
GNVC: 0.53 (-0.04)
Michael Richman Appointed To GenVec Board Of Directors
PR Newswire - Wed Apr 22, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that the Board of Directors of GenVec, Inc. appointed Michael Richman as a director of the company.
GNVC: 0.53 (-0.04)
GenVec Announces Collaboration with the Laboratory of Malaria Immunology & Vaccinology
PR Newswire - Tue Apr 21, 7:01AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that it has signed a research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
GNVC: 0.53 (-0.04)
GenVec Reports Second Quarter 2016 Financial Results
PR Newswire - Fri Aug 05, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the second quarter ended June 30, 2016. For the three months ended June 30, 2016, the company reported a net loss of $1.2 million or $0.06 per share on revenues of $26,000. This compares to a net loss of $1.9 million or $0.11 per share on revenues of $127,000 for the same period in the prior year. For the six months ended June 30, 2016, the company reported a net loss of $3.1 million or $0.16 per share on revenues of $0.3 million. This compares to a net loss of $3.4 million or $0.21 per share on revenues of $0.5 million for the same period in the prior year. The company ended the second quarter of 2016 with $9.6 million in cash and cash equivalents.
GNVC: 0.53 (-0.04)
Can DENTSPLY (XRAY) Spring an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:15AM CDT
DENTSPLY SIRONA Inc. (XRAY) is expected to report second-quarter 2016 results on Aug 5.
GNVC: 0.53 (-0.04), ANIP: 59.74 (-1.12), XRAY: 61.46 (-0.04), COO: 185.92 (-0.46)
GenVec Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the first quarter ended March 31, 2016. For the three months ended March 31, 2016, the company reported a net loss of $1.9 million, or $0.11 per share, compared with a net loss of $1.5 million, or $0.09 per share, for the three months ended March 31, 2015. The company ended the first quarter with $6.9 million in cash, cash equivalents, and liquid investments.
GNVC: 0.53 (-0.04)
GenVec Provides Update on Hearing Loss Clinical Program
PR Newswire - Mon May 02, 6:00AM CDT
GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced today that it was notified by its collaborator Novartis that the Data Safety Monitoring Board (DSMB) for the Phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss has recommended that the trial continue, subject to approval by the U.S. Food and Drug Administration (FDA). This recommendation was based on a review of safety and efficacy data from the nine patients currently enrolled in the study. Novartis is developing CGF166, GenVec's lead product candidate for hearing loss, under a Research Collaboration and License Agreement with GenVec. As previously disclosed, on January 8, 2016, GenVec was notified by Novartis that enrollment was paused in the clinical study for CGF166 in accordance with criteria in the trial protocol.
GNVC: 0.53 (-0.04), NVS: 78.77 (-0.57)
GenVec Provides Investor Update
PR Newswire - Wed Jan 20, 6:00AM CST
GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, provided an update to investors on recent developments and the company's strategic focus.
GNVC: 0.53 (-0.04), NVS: 78.77 (-0.57)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of GenVec, Inc. (GNVC)
PR Newswire - Mon Jan 11, 11:56AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of GenVec, Inc. ("GenVec" or the "Company"
(Nasdaq: GNVC). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. GNVC: 0.53 (-0.04)
GenVec Receives Notice of Allowance for Patent Application Providing Broad Protection of Its Gorilla Adenovectors
PR Newswire - Wed Dec 02, 7:00AM CST
GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced today that it received a notice of allowance for its patent application entitled "Affenadenovirus (Gorilla) or Adenoviral Vectors and Methods of Use" from the U.S. Patent and Trademark Office. The allowed claims cover composition of matter for the company's proprietary adenovectors isolated from mountain gorillas, including potential adjustments and additions that may be introduced to engineer these vectors for optimal suitability and performance in a variety of therapeutic and vaccine applications. One key advantage of our approach is that most people do not have pre-existing immunity to gorilla vectors. Such pre-existing immunity can interfere with vectors derived from more commonly encountered viruses and viral serotypes.
GNVC: 0.53 (-0.04)
GenVec Reports Third Quarter 2015 Financial Results
PR Newswire - Mon Nov 09, 7:00AM CST
GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, reported financial results for the third quarter ended September 30, 2015. For the three months ended September 30, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.2 million, compared with a net loss of $1.6 million, or $0.10 per share, on revenues of $0.3 million, for the same period in the prior year. For the nine months ended September 30, 2015, GenVec reported a net loss of $4.9 million, or $0.30 per share, on revenues of $0.7 million, compared with a net loss of $4.2 million, or $0.27 per share, on revenues of $2.5 million, for the same period in the prior year. GenVec ended the third quarter of 2015 with $9.9 million in cash, cash equivalents and investments.
GNVC: 0.53 (-0.04)
GenVec Expands I.P. Portfolio With Issuance Of U.S. And European Patents For Monkey Adenoviral Vectors
PR Newswire - Mon Sep 28, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that on September 15, 2015, the U.S. Patent and Trademark Office issued patent 9133248, covering methods of propagating proprietary gene delivery adenovectors isolated from new and old world monkeys. This patent complements European Patent No. 2498791, "Methods of Propagating Monkey Adenoviral Vectors". Patent applications in this family are also pending in Japan, China, India and Canada as well as other inventive claims in divisional applications. GenVec's monkey adenovectors provide additional, complementary features to our already broad platform providing greater flexibility to efficiently address a wide variety of gene delivery applications. In addition, GenVec's entire portfolio of vectors grow to high yields in our proprietary cell lines and can be readily manufactured under GMP conditions making them strong candidates for therapeutic use.
GNVC: 0.53 (-0.04)
GenVec (GNVC) Shows Strength: Stock Moves Up 18.7%
Zacks Equity Research - Zacks Investment Research - Mon Sep 21, 7:51AM CDT
GenVec, Inc. (GNVC) was a big mover last session, as its shares rose almost 19% on the day.
GNVC: 0.53 (-0.04), GILD: 78.38 (+0.46)
GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines
PR Newswire - Wed Jun 03, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced a multi-faceted collaboration with Dr. David T. Curiel and his team from the School of Medicine at Washington University at St. Louis (WUSTL). Dr. Curiel is the director of the Biologic Therapeutic Center and the Cancer Biology Division within the Department of Radiation Oncology.
GNVC: 0.53 (-0.04)
GenVec Highlights Proprietary Gorilla Vectors At ASGCT Presentation
PR Newswire - Thu May 14, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) announced today that Douglas E. Brough, the company's chief scientific officer, gave a presentation entitled "Gorilla Adenovirus Vectors for Molecular Therapeutics and Vaccines" at the 18th Annual Meeting of the American Society of Gene & Cell Therapy. The presentation highlighted the results of preclinical research conducted using the company's propriety adenovirus vectors originally isolated from mountain gorillas. These adenovectors have demonstrated superior performance to induce high level durable antigen specific antibody and T cell responses in GenVec's preclinical models for respiratory syncytial virus, herpes simplex virus, and malaria from a single administration. GenVec is working to test these 'gorilla Ads' in a variety of configurations through research conducted by its own laboratories and through collaborations and partnerships.
GNVC: 0.53 (-0.04)
Michael Richman Appointed To GenVec Board Of Directors
PR Newswire - Wed Apr 22, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that the Board of Directors of GenVec, Inc. appointed Michael Richman as a director of the company.
GNVC: 0.53 (-0.04)
GenVec Announces Collaboration with the Laboratory of Malaria Immunology & Vaccinology
PR Newswire - Tue Apr 21, 7:01AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that it has signed a research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
GNVC: 0.53 (-0.04)
